Merck/Sanofi Pasteur (MSP)

  1. Home
  2.  / 
  3. Partners & Products
  4.  / 
  5. Vaccines
  6.  / 
  7. Merck/Sanofi Pasteur (MSP)

Vaxelis Logo

Vaxelis™ the much anticipated hexavalent vaccine developed collaboratively between Merck & Sanofi Pasteur is finally available!  Approved by the FDA in 2018 and given the recommendation by the ACIP, Vaxelis™ will be an important leap forward in reducing the number of injections required for infant immunization.

The Vaxelis™ pricing program is a separate and new contract from other Sanofi Pasteur vaccines. For member practices who are interested in qualifying for the performance pricing, there is a marketshare component.  For details please reach out to us at (818) 332-7057 or by e-mail at ten.gppmnull@ofni.

MPPG Members may participate in the Vaxelis™ performance pricing program by completing the performance pricing form.

More details about Vaxelis™ may be found at website

Client Testimonials

"Our savings on our malpractice insurance alone were significant. I highly recommend MPPG."

Subscribe for Email Updates

  • This field is for validation purposes and should be left unchanged.

News Archives